Boston Scientific Posts 7% Organic Sales Growth in Q2
BSX is trading near its 52-week low of $42.2 (11% above the low).
Summary
Boston Scientific reported 7.0% organic sales growth for the second quarter, a solid top-line result that suggests underlying demand remains healthy despite recent headwinds. The company's Q2 results beat estimates on cardiovascular strength, and profit advanced in the quarter. This follows the late-July restructuring announcement and the May disclosure of a Watchman slowdown, making the organic growth figure a key read on the core business. The number indicates the company is still expanding its base business at a respectable clip, which could ease concerns about the Watchman impact. No profit or guidance details were provided in the headline, so the full earnings picture remains incomplete. Investors will look to the complete release for margin trends and any update to the full-year outlook.
At the time of this announcement, BSX was trading at $46.80 on NYSE in the Life Sciences sector, with a market capitalization of approximately $68.5B. The 52-week trading range was $42.20 to $109.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.